Immunomodulation by the new synthetic compound BM 12.531, 2-[2-cyanaziridinyl-(1)]-[2-carbamoylaziridinyl-(1)]-propane (azimexone).
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects; D001388:Aziridines / Q000494:pharmacology*; D001389:Azirines / Q000494:pharmacology*; D001853:Bone Marrow / Q000473:pathology; D003208:Concanavalin A / Q000494:pharmacology; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007958:Leukocyte Count; D008070:Lipopolysaccharides / Q000494:pharmacology; D008213:Lymphocyte Activation; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D010835:Phytohemagglutinins / Q000494:pharmacology; D051381:Rats; D012513:Sarcoma, Experimental / Q000276:immunology* / Q000473:pathology
D001388:Aziridines; D001389:Azirines; D008070:Lipopolysaccharides; D010835:Phytohemagglutinins; D003208:Concanavalin A; C016866:azimexon